Baird analyst Brian Skorney raised the firm’s price target on Soleno Therapeutics (SLNO) to $121 from $105 and keeps an Outperform rating on the shares. The firm updated its model after Q2 Vykat sales blew out expectations.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SLNO:
- Soleno Therapeutics Announces Public Stock Offering
- Soleno Therapeutics prices 2.35M sharesat $85.00 in public offering
- Soleno Therapeutics announces proposed $200M public offering
- Soleno Therapeutics sees Q2 VYKAT XR revenue $31M-$33M
- Soleno Therapeutics price target raised to $115 from $108 at Stifel